Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Sundell, Karen L.
54  Ergebnisse:
Personensuche X
?
1

Recruitment strategies and tactics for INTERCEPT‐AD: A phas..:

Moxon, Robyn ; Feaster, Todd ; Carroll, Alyssa...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
2

Topline results of INTERCEPT‐AD: A phase I trial of Aβ olig..:

Siemers, Eric R ; Feaster, Todd ; Skljarevski, Vladimir...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
3

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial w..:

Feaster, Todd ; Ziemba, Shane ; Sundell, Karen L...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
4

Magnetic resonance imaging measures of brain atrophy from t..:

Schwarz, Adam J. ; Sundell, Karen L. ; Charil, Arnaud...
Alzheimer's & Dementia: Translational Research & Clinical Interventions.  5 (2019)  1 - p. 328-337 , 2019
Link: https://doi.org/10.1016/..
 
?
5

O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXP..:

Shcherbinin, Sergey ; Liu, Peng ; Fleisher, Adam S....
Alzheimer's & Dementia.  14 (2018)  7S_Part_19 - p. , 2018
Link: https://doi.org/10.1016/..
 
?
6

Central pharmacodynamic activity of solanezumab in mild Alz..:

Willis, Brian A. ; Sundell, Karen ; Lachno, D. Richard...
Alzheimer's & Dementia: Translational Research & Clinical Interventions.  4 (2018)  1 - p. 652-660 , 2018
Link: https://doi.org/10.1016/..
 
?
7

IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXP..:

Shcherbinin, Sergey ; Liu, Peng ; Fleisher, Adam S....
Alzheimer's & Dementia.  14 (2018)  7S_Part_3 - p. , 2018
Link: https://doi.org/10.1016/..
 
?
8

Use of white matter reference regions for detection of chan..:

Fleisher, Adam S. ; Joshi, Abhinay D. ; Sundell, Karen L....
Alzheimer's & Dementia.  13 (2017)  10 - p. 1117-1124 , 2017
Link: https://doi.org/10.1016/..
 
?
9

[IC‐P‐043]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEG..:

Schwarz, Adam J. ; Sundell, Karen L. ; Lachno, David Richard...
Alzheimer's & Dementia.  13 (2017)  7S_Part_1 - p. , 2017
Link: https://doi.org/10.1016/..
 
?
10

[P1–049]: SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMAC..:

Dean, Robert A. ; Sundell, Karen L. ; Lachno, David Richard...
Alzheimer's & Dementia.  13 (2017)  7S_Part_5 - p. , 2017
Link: https://doi.org/10.1016/..
 
?
11

[P2–002]: EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGEN..:

Schwarz, Adam J. ; Sundell, Karen L. ; Lachno, David Richard...
Alzheimer's & Dementia.  13 (2017)  7S_Part_12 - p. , 2017
Link: https://doi.org/10.1016/..
 
?
12

[O5–01–01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PAT..:

Mintun, Mark A. ; Devous Sr, Michael D. ; Lu, Ming...
Alzheimer's & Dementia.  13 (2017)  7S_Part_30 - p. , 2017
Link: https://doi.org/10.1016/..
 
?
13

Function and clinical meaningfulness of treatments for mild..:

Siemers, Eric ; Holdridge, Karen Chilcott ; Sundell, Karen L..
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.  2 (2016)  1 - p. 105-112 , 2016
Link: https://doi.org/10.1016/..
 
?
14

Quantile regression to characterize solanezumab effects in ..:

Chen, Yun‐Fei ; Ma, Xiwen ; Sundell, Karen...
Alzheimer's & Dementia: Translational Research & Clinical Interventions.  2 (2016)  3 - p. 192-198 , 2016
Link: https://doi.org/10.1016/..
 
?
15

Amyloid status imputed from a multimodal classifier includi..:

Tosun, Duygu ; Chen, Yun-Fei ; Yu, Peng...
Alzheimer's & Dementia.  12 (2016)  9 - p. 977-986 , 2016
Link: https://doi.org/10.1016/..
 
1-15